Clinical trials for lung cancer

129 currently recruiting clinical trials

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
Hoffmann-La Roche
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
AstraZeneca
Phase 3 Lung cancer
#NCT06875310
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C None Systemic Treatment-Naive
Targeted therapy Targeted therapy
CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Hôpital Cochin (Paris ), Centre Jean Perrin (Clermont Ferrand )
Mirati Thérapeutique Inc.
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Negative (< 1%) None Systemic Treatment-Naive
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier de Cornouaille (Quimper), Centre Antoine Lacassagne (Nice), Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille), Centre Hospitalier Universitaire de Nîmes (Nîmes) (and 24 more...)
Amgen
Phase 3 Lung cancer
#NCT06119581
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C Systemic Treatment-Naive
BRAF EGFR HER2 MET NTRK-1/2/3 RET ROS-1 Immunotherapy Chemotherapy Targeted therapy
Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille)
Eli Lilly et compagnie
Phase 3 Lung cancer
#NCT06635824
NSCLC (Non-Small Cell Lung Cancer) Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 Immunotherapy Chemotherapy
ALK BRAF EGFR KRAS G12C KRAS non G12C MET RET ROS-1 Systemic Treatment-Naive Car-T
Hôpital Privé du Confluent - Vivalto Santé (Nantes), Hôpital Ambroise-Paré AP-HP (Boulogne-Billancourt), CHU de Rennes - Hôpital Pontchaillou (Rennes), Ghrmsa - Hôpital Emile Muller (Mulhouse), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain) (and 10 more...)
Genmab